ADC Therapeutics SA (ADCT)

4.4400 -0.3400 (-7.11%) At close: 04:00PM EDT

ADC Therapeutics SA

Biopôle
Route de la Corniche 3B
Epalinges 1066
Switzerland
41 21 653 02 00
https://www.adctherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 273

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Ameet Mallik M.B.A., M.S.	CEO & Director	1.84M	N/A	1973
Mr. Jose I. Carmona M.B.A.	Chief Financial Officer	884.86k	N/A	1972
Dr. Mohamed Zaki M.D., Ph.D.	Chief Medical Officer	2.41M	N/A	1965
Ms. Lisa Michelle Kallebo	Corporate Controller & Chief Accounting Officer	N/A	N/A	N/A
Dr. Michael Mulkerrin Ph.D.	Chief Technical Operations Officer	N/A	N/A	1955
Dr. Patrick van Berkel Ph.D.	Chief Scientific Officer	N/A	N/A	1968
Amanda Hamilton	Investor Relations Officer	N/A	N/A	N/A
Mr. Peter J. Graham Esq.	Chief Legal Officer	N/A	N/A	1967
Ms. Eugenia Litz	Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Kimberly Pope	Senior VP & Chief People Officer	N/A	N/A	1967

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Corporate governance

ADC Therapeutics SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.